ARMO Biosciences (NASDAQ:ARMO) Receives New Coverage from Analysts at BMO Capital Markets

Stock analysts at BMO Capital Markets started coverage on shares of ARMO Biosciences (NASDAQ:ARMO) in a research note issued to investors on Tuesday, February 20th, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $75.00 price target on the stock. BMO Capital Markets’ target price would suggest a potential upside of 62.97% from the company’s current price.

Separately, Jefferies Group started coverage on ARMO Biosciences in a report on Tuesday, February 20th. They set a “buy” rating and a $61.00 target price on the stock.

Shares of ARMO Biosciences (NASDAQ:ARMO) traded down $3.74 during trading hours on Tuesday, hitting $46.02. The company had a trading volume of 175,792 shares, compared to its average volume of 229,197. ARMO Biosciences has a twelve month low of $27.00 and a twelve month high of $57.19.

WARNING: This news story was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at

About ARMO Biosciences

ARMO Biosciences, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company’s platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects that induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8+ T cells in cancer patients.

Receive News & Ratings for ARMO Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply